# Penetration Testing Implementation Guide

## Overview

A **Penetration Test (Pen Test)** is a controlled, authorized security assessment where an external security firm attempts to breach TheraGenome systems to identify vulnerabilities before attackers do. This is a **HIPAA requirement** and **blocking item** for production deployment.

**HIPAA Requirement:** 45 CFR §164.308(a)(3) - "Conduct or arrange for periodic security evaluations, including penetration testing and vulnerability assessments"

**Compliance Status:** 🔴 **BLOCKING** - Cannot deploy to production without completed pen test + remediation

---

## Part 1: Penetration Testing Scope Definition

### 1.1 What Will Be Tested?

**IN SCOPE (What gets tested):**

```
NETWORK & INFRASTRUCTURE:
✅ External network perimeter (Ingress controllers, load balancers)
✅ VPN/remote access controls (if applicable)
✅ Firewall rules and network segmentation
✅ DNS and network services
✅ AWS infrastructure configuration and access controls

APPLICATIONS:
✅ API endpoints (REST, GraphQL, variant analysis)
✅ Web applications (if any front-end exists)
✅ Authentication/authorization mechanisms
✅ Session management (JWT, cookies)
✅ Input validation (SQL injection, XSS, LDAP injection)
✅ Business logic flaws
✅ API rate limiting and DDoS protections

DATA & SYSTEMS:
✅ Database access controls and encryption
✅ Data exposure via application queries
✅ Backup systems and recovery processes
✅ Audit logging and log access controls
✅ PHI exposure vectors

CLOUD INFRASTRUCTURE (AWS):
✅ S3 bucket configurations and access controls
✅ RDS enforcement of SSL/encryption
✅ KMS key access and policies
✅ IAM role permissions and service account hardening
✅ Security group and ACL configurations
```

**OUT OF SCOPE (What won't be tested):**

```
❌ Social engineering or phishing (discuss before including)
❌ Physical security at data centers (AWS's responsibility)
❌ Denial-of-service testing (unless agreed for capacity testing)
❌ Production database attacks (only staging environment)
❌ Third-party SaaS vulnerabilities (not your code to fix)
❌ Open-source library vulnerabilities (unless in your code)
❌ Legal/compliance review (outside pen tester's scope)
```

### 1.2 Testing Environment

**PRIMARY ENVIRONMENT: Staging (NOT Production)**

```
STAGING ENVIRONMENT REQUIREMENTS:

Isolation:
  ✅ Staging must be completely isolated from production
  ✅ Production database must NOT be cloned to staging
  ✅ Use anonymized/synthetic PHI only for testing
  ✅ Network ACLs prevent access between staging/prod

Data:
  ✅ Use de-identified patient records (no real PHI)
  ✅ Sample genomic data without identifiers
  ✅ Test data created specifically for testing
  ✅ Purge test data immediately after testing

Access:
  ✅ Testing period has 24/7 access (coordinate handoff)
  ✅ Known IP addresses for tester's network
  ✅ No production traffic during testing
  ✅ Kill switches available if system becomes compromised

Monitoring:
  ✅ Security team monitors for actual exploits
  ✅ Alert on suspicious patterns during testing
  ✅ Differentiate pen tester activity from real attacks
```

### 1.3 Testing Timeline & Windows

**Recommended Schedule:**

```
TIMELINE OVERVIEW:

Week 1: Reconnaissance & Enumeration (2-3 days)
  - Passive information gathering
  - Network scanning and mapping
  - Technology stack identification
  - Version detection (web servers, databases, frameworks)

Week 1-2: Active Testing & Exploitation (3-5 days)
  - Vulnerability scanning with automated tools
  - Manual vulnerability testing
  - Exploitation of identified weaknesses
  - Access escalation attempts
  - Application logic testing

Week 2-3: Analysis & Report Writing (3-5 days)
  - Detailed documentation of all findings
  - Severity rating (CVSS scoring)
  - Proof-of-concept demonstrations
  - Remediation recommendations
  - Executive summary preparation

TYPICAL DURATION: 2-3 weeks for comprehensive assessment
COST RANGE: $15,000 - $50,000 depending on scope
```

**Best Testing Window:**

```
AVOID:
  ❌ Production deployment windows
  ❌ Critical business cycles (month-end, year-end)
  ❌ Major system maintenance windows
  ❌ Times when incident response team unavailable

OPTIMAL:
  ✅ Mid-week (Tuesday-Thursday)
  ✅ Business hours preferred (for incident response prep)
  ✅ Post-deployment window (systems stable)
  ✅ Planned well in advance (4-6 weeks lead time)
```

### 1.4 Tester Coordination

**Roles During Testing:**

```
SECURITY LEAD (TheraGenome):
  - Single point of contact for tester
  - Monitors for legitimate vs malicious activity
  - Can halt testing if system damage occurs
  - Logs all tester activities and findings
  - Coordinates incident response if actual breach occurs

INCIDENT RESPONSE TEAM:
  - On standby during testing hours
  - Ready to respond if tester causes outage
  - Validates findings reported by tester
  - Tests recovery procedures if needed

INFRASTRUCTURE TEAM:
  - Monitors system health during testing
  - Ready to scale/remediate if needed
  - Tracks resource usage spikes
  - Performs post-test forensics

TESTER (External Firm):
  - Reports all findings in real-time
  - Demonstrates vulnerabilities safely
  - Does NOT modify production data
  - Follows ROE (Rules of Engagement)
```

---

## Part 2: Vendor Selection & RFP Process

### 2.1 Security Firm Qualification Criteria

**MUST HAVE:**

```
☑ HIPAA Penetration Testing Experience
  - Minimum 5+ years with healthcare clients
  - Portfolio of healthcare company references
  - Understanding of HIPAA-specific requirements
  - Experience testing PHI exposure vectors

☑ Relevant Certifications
  - CEH (Certified Ethical Hacker) - primary tester minimum
  - OSCP (Offensive Security Certified Professional) - preferred
  - GPEN (GIAC Penetration Tester) - accepted
  - GWAPT (GIAC Web Application Penetration Tester) - for web testing

☑ Insurance & Liability Coverage
  - General liability insurance ($1M+ recommended)
  - Professional liability ($2M+ recommended)
  - E&O (Errors & Omissions) insurance
  - Certificate of Insurance provided before engagement

☑ Legal Framework
  - Willing to sign NDA (protect findings confidentiality)
  - Willing to sign ROE (Rules of Engagement)
  - Clear liability limitations
  - Data destruction agreement (delete notes/screenshots)

☑ Technical Capabilities
  - Experience with Cloud platforms (AWS required)
  - Kubernetes security testing (if using K8s)
  - Database security (PostgreSQL)
  - Application security (REST APIs, microservices)
  - Container security (Docker)
```

**NICE TO HAVE:**

```
✓ OHITAC (Organization for Cybersecurity & Infrastructure Assurance) membership
✓ SOC 2 Type II compliance (shows controlled processes)
✓ Prior pen test experience with genomics/biotech
✓ Experience with machine learning/AI security
✓ Emergency response capability (24/7 contact)
✓ Onsite testing availability (vs remote-only)
```

### 2.2 RFP (Request for Proposal) Template

```
═══════════════════════════════════════════════════════════════════════════
REQUEST FOR PROPOSAL: PENETRATION TESTING ASSESSMENT
TheraGenome, Inc. - Healthcare Genomics Platform

Issue Date: April [DATE], 2026
Proposal Due Date: [2 weeks from issue]
Estimated Project Start: May [DATE], 2026
Budget Range: $20,000 - $40,000

═══════════════════════════════════════════════════════════════════════════

EXECUTIVE SUMMARY:

TheraGenome is a HIPAA-covered entity providing genomic analysis and precision 
medicine services. We are seeking a qualified penetration testing firm to conduct 
a comprehensive security assessment of our platform before production deployment.

This proposal requests assessment of our cloud-based microservices architecture 
running on AWS infrastructure, including:  
  - FastAPI backend (Python)
  - Deno/TypeScript variant analysis API
  - PostgreSQL database (patient records)
  - Kubernetes orchestration (container deployment)
  - Observability stack (Prometheus, Grafana, OpenTelemetry)

═══════════════════════════════════════════════════════════════════════════

1. SCOPE OF WORK

1.1 INCLUDED TESTING (In Scope):

NETWORK ASSESSMENT:
  - External perimeter scanning and enumeration
  - AWS infrastructure configuration review
  - Security group and network ACL evaluation
  - DNS and routing security
  - Load balancer and Ingress controller configuration

APPLICATION TESTING:
  - API endpoint security assessment (REST endpoints)
  - Authentication/authorization testing
  - Session management and token validation
  - Input validation (SQL injection, XSS, command injection)
  - Business logic vulnerability identification
  - Rate limiting and DDoS protection testing

INFRASTRUCTURE TESTING:
  - Container and Kubernetes security
  - Database access controls and encryption validation
  - AWS S3, RDS, KMS configuration review
  - IAM policy assessment
  - Backup and recovery security

DATA & COMPLIANCE:
  - PHI exposure identification
  - Encryption validation (in-transit and at-rest)
  - Access control verification
  - Audit logging assessment
  - HIPAA control validation

1.2 OUT OF SCOPE:

The following are NOT included in this assessment:
  ❌ Production environment testing (staging only)
  ❌ Social engineering or physical security testing
  ❌ Sustained denial-of-service testing
  ❌ Third-party SaaS vendor assessment
  ❌ Legal/compliance review (outside scope)
  ❌ Post-remediation verification testing (separate engagement)

═══════════════════════════════════════════════════════════════════════════

2. TESTING ENVIRONMENT

2.1 STAGING ENVIRONMENT DETAILS:

Infrastructure:
  - AWS Account (staging): [ACCOUNT_ID]
  - Kubernetes Cluster: [CLUSTER_NAME] (staging)
  - Primary API: https://staging-api.theragenome.internal
  - Variant API: https://staging-variant.theragenome.internal
  - Database: PostgreSQL 15 (non-production replica, anonymized data)
  - Number of API endpoints: [COUNT]
  - Expected concurrent users during test: [NUMBER]

Data:
  - Synthetic patient records (no real PHI)
  - Anonymized genomic data samples
  - Test data: ~10,000 records
  - Data refresh frequency: Daily (test data reset nightly)
  - Production database: NOT accessible from staging (air-gapped)

Access:
  - VPN access provided for tester IP ranges: [CIDRS]
  - Tester GitHub/GitLab access if code review needed
  - AWS sandbox account credentials (temporary, revoked post-testing)
  - Database read access (if needed for assessment)
  - 24/7 testing window: [DATES/TIME]

═══════════════════════════════════════════════════════════════════════════

3. TESTING APPROACH & METHODOLOGY

3.1 TESTING PHASES:

Phase 1: Reconnaissance & Passive Information Gathering (2 days)
  - Passive DNS enumeration
  - Public information gathering
  - WHOIS data review
  - Technology stack identification (web server, frameworks, versions)
  - No active scanning or intrusive testing

Phase 2: Scanning & Active Enumeration (1-2 days)
  - Network port scanning
  - Service enumeration
  - Vulnerability scanning (Nessus, OpenVAS, custom tools)
  - Version detection for software services
  - Unintended exposure discovery (S3 buckets, etc.)

Phase 3: Manual Testing & Exploitation (3-5 days)
  - Manual vulnerability verification
  - Web application testing (OWASP Top 10)
  - API endpoint testing
  - Authentication bypass attempts
  - Authorization/access control testing
  - Business logic flaw identification
  - Data exposure testing

Phase 4: Post-Exploitation & Impact Analysis (2-3 days)
  - Lateral movement testing (if network access obtained)
  - Privilege escalation attempts
  - Data exfiltration testing (controlled, non-destructive)
  - Persistence mechanism investigation
  - Impact and severity assessment

3.2 TOOLS & METHODOLOGIES:

The Tester may use industry-standard tools including:
  - Burp Suite (web application security)
  - OWASP ZAP (API and web testing)
  - Nessus/OpenVAS (vulnerability scanning)
  - Metasploit (exploitation framework)
  - Custom tools and manual testing
  - AWS-specific security tools (IAM policy validator, etc.)
  - Cloud security assessment frameworks

Methodology: 
  - NIST Cybersecurity Framework
  - OWASP Testing Guide v4.2
  - SANS Pen Testing
  - Industry best practices

═══════════════════════════════════════════════════════════════════════════

4. DELIVERABLES

4.1 REPORT CONTENTS (Required):

Executive Summary (2-3 pages)
  - High-level overview of findings
  - Risk matrix (hits vs miss assessment)
  - Recommendations for leadership
  - Overall security posture statement

Detailed Findings (15-25 pages)
  Each vulnerability includes:
    - Finding title and description
    - CVSS v3.1 severity score
    - OWASP or CWE classification
    - Step-by-step reproduction steps
    - Proof-of-concept (screenshots, logs)
    - Impact analysis (what could attacker do)
    - Affected systems/endpoints
    - Remediation recommendations
    - Severity rating: CRITICAL / HIGH / MEDIUM / LOW / INFORMATIONAL

Technical Appendix (10-20 pages)
  - Tools and versions used
  - Scan results (raw output if helpful)
  - Network diagram (if discovered)
  - Vulnerability details (CVSS scores)
  - Test logs and activity timeline

4.2 REPORT FORMAT:

  - PDF format (professional formatting)
  - Microsoft Word version (for internal editing)
  - Executive briefing slides (15-20 slides)
  - Raw tool output (for detailed analysis, as appendix)
  - Vulnerability timeline spreadsheet (findings by date/impact)

4.3 CONFIDENTIALITY:

  - Report marked "CONFIDENTIAL - Attorney Client Privileged"
  - Limited distribution (Compliance Officer, CISO, Legal)
  - All digital copies encrypted
  - Physical copies labeled and stored securely
  - Destruction agreement: Tester deletes all testing notes/screenshots

═══════════════════════════════════════════════════════════════════════════

5. PROJECT TIMELINE

Start Date: May [DATE], 2026
Duration: 3 weeks

Week 1:
  - Kickoff meeting (Monday)
  - Environment access provisioning
  - Reconnaissance & passive enumeration
  - Initial vulnerability scanning

Week 2:
  - Active testing & exploitation begins
  - Regular status updates (daily)
  - Vulnerability discovery and documentation

Week 3:
  - Exploitation continues
  - Post-exploitation analysis
  - Report writing and compilation

Week 4 (Buffer):
  - Report finalization
  - Executive briefing presentation
  - Final delivery

Delivery Date: Report due within 2 weeks of testing completion
Presentation: 2-3 days after report delivery

═══════════════════════════════════════════════════════════════════════════

6. QUALIFICATIONS & REQUIREMENTS

6.1 FIRM QUALIFICATIONS:

Required Certifications:
  ☑ Lead tester must hold CEH, OSCP, GPEN, or equivalent
  ☑ Secondary team members with relevant certifications
  ☑ HIPAA training certification (required)

Experience:
  ☑ Minimum 5 years healthcare/HIPAA-related pen testing
  ☑ AWS penetration testing experience (required)
  ☑ Kubernetes security assessment experience (preferred)
  ☑ Healthcare client references (provide 2-3)

Insurance & Legal:
  ☑ General Liability insurance: Minimum $1M
  ☑ Professional Liability insurance: Minimum $2M
  ☑ Certificate of Insurance (current) provided by [DATE]
  ☑ Willing to sign NDA and Rules of Engagement

6.2 BACKGROUND CHECKS:

All personnel with system access must:
  ☑ Pass background check (TheraGenome policy)
  ☑ Sign NDA and Rules of Engagement
  ☑ Agree to data destruction procedures
  ☑ Accept liability limitations

═══════════════════════════════════════════════════════════════════════════

7. LEGAL TERMS & CONDITIONS

7.1 RULES OF ENGAGEMENT (ROE):

The Tester agrees to:
  ✅ Only test staging environment (no production access)
  ✅ Not exceed defined scope without written approval
  ✅ Report all findings immediately upon discovery
  ✅ Not destroy, modify, or exfiltrate non-test data
  ✅ Maintain confidentiality of all findings
  ✅ Follow all applicable laws and regulations
  ✅ Halt testing immediately if directed by security lead
  ✅ Provide proof of technical competency if requested

TheraGenome agrees to:
  ✅ Provide agreed-upon system access
  ✅ Maintain staging environment stability
  ✅ Not hold tester liable for testing-related downtime
  ✅ Pay invoices within 30 days of completion
  ✅ Maintain confidentiality of firm's methodologies

7.2 LIMITATION OF LIABILITY:

  - TheraGenome assumes all risk of testing activities
  - Tester not liable for unintended system impact
  - Both parties maintain liability insurance
  - Either party can halt testing with 24 hours notice

7.3 INTELLECTUAL PROPERTY:

  - Tester retains IP for tools/scripts developed
  - TheraGenome retains all findings and recommendations
  - Both parties may anonymously reference engagement

═══════════════════════════════════════════════════════════════════════════

8. PROPOSAL REQUIREMENTS

Please provide in your proposal:

1. Executive Summary (1 page)
   - Understanding of TheraGenome's requirements
   - Your firm's relevant experience

2. Proposed Approach (2-3 pages)
   - Your testing methodology
   - Phases and timeline
   - Resource allocation

3. Team Qualifications (1-2 pages)
   - Lead tester resume/certifications
   - Key team member credentials
   - HIPAA training proof

4. Pricing (1 page)
   - Total project cost
   - Breakdown by phase (if applicable)
   - Payment terms
   - Optional services/add-ons

5. References (1 page)
   - 3 healthcare client references
   - Contact info and project details

6. Insurance Documentation
   - Certificate of Insurance (attached)

═══════════════════════════════════════════════════════════════════════════

9. EVALUATION CRITERIA

Proposals will be evaluated on:

  1. QUALIFICATIONS (40%)
     - Team certifications and experience
     - Healthcare/HIPAA background
     - Technical capabilities match

  2. APPROACH & METHODOLOGY (25%)
     - Comprehensiveness of testing plan
     - Alignment with best practices
     - Understanding of our environment

  3. SCHEDULE & AVAILABILITY (15%)
     - Can start by May [DATE]
     - Timing fits our production timeline
     - Resource availability confirmed

  4. COST (15%)
     - Competitive pricing
     - Value relative to scope
     - Payment terms acceptable

  5. REFERENCES (5%)
     - Quality of client references
     - Similar project experience
     - Client satisfaction indicators

═══════════════════════════════════════════════════════════════════════════

10. SUBMISSION & QUESTIONS

Proposal Submission:
  Send to: [COMPLIANCE_OFFICER@THERAGENOME.COM]
  Format: PDF + Word doc
  Deadline: [DATE] at 5 PM EST

Questions?
  Contact: [Security Lead Name, Email, Phone]
  Response time: 24-48 hours

Selection Timeline:
  Proposals due: [DATE]
  Selection announcement: [DATE + 1 WEEK]
  Kick-off meeting: [DATE + 2 WEEKS]

═══════════════════════════════════════════════════════════════════════════

Authorized By:

Compliance Officer: _________________________ Date: _______

General Counsel: _________________________ Date: _______

CISO/Security Lead: _________________________ Date: _______
```

---

## Part 3: Vulnerability Assessment & Remediation

### 3.1 Vulnerability Classification

**SEVERITY RATINGS (CVSS v3.1 based):**

```
🔴 CRITICAL (CVSS 9.0-10.0)
   - Unauthenticated RCE (Remote Code Execution)
   - SQL Injection leading to database breach
   - Complete PHI exposure (bulk patient data downloadable)
   - Authentication bypass affecting all users
   - Unencrypted data transmission of PHI
   
   Required Response Time: 24 hours
   Remediation: MANDATORY before production
   Example: "API endpoint allows SQL injection via patient_id parameter"

🔴 HIGH (CVSS 7.0-8.9)
   - Authenticated privilege escalation to admin
   - Significant PHI exposure (partial data leak)
   - Weak encryption (self-signed certs, outdated TLS)
   - Missing audit logging on sensitive operations
   - Insufficient access controls on database
   
   Required Response Time: 1 week
   Remediation: MANDATORY before production
   Example: "Analyst role can access patient SSN field via API query"

🟠 MEDIUM (CVSS 4.0-6.9)
   - Information disclosure (version numbers, stack traces)
   - Weak password policy enforcement
   - Missing rate limiting on API endpoints
   - Insufficient logging of security events
   - Unpatched non-critical vulnerabilities
   
   Required Response Time: 2-4 weeks
   Remediation: STRONGLY RECOMMENDED before production
   Example: "Error messages disclose database schema information"

🟡 LOW (CVSS 0.1-3.9)
   - Banner grabbing disclosure
   - Missing security headers
   - Configuration recommendations
   - Documentation improvements
   
   Required Response Time: 60 days
   Remediation: RECOMMENDED for hardening
   Example: "Missing Content-Security-Policy header"

⚪ INFORMATIONAL
   - Best practice recommendations
   - Future security improvements
   - Process recommendations
   
   Required Response Time: As scheduled
   Remediation: OPTIONAL process improvements
   Example: "Recommend implementing Web Application Firewall (WAF)"
```

### 3.2 Remediation Workflow

```
PHASE 1: TRIAGE & PRIORITIZATION (Immediate)
  1. Receive pen test report
  2. Security lead reviews all findings
  3. CRITICAL items identified
  4. Create remediation task list
  5. Assign owners to each finding
  6. Establish target remediation dates

PHASE 2: CRITICAL FIXES (Within 48 hours)
  For CRITICAL vulnerabilities:
  1. Convene emergency response team
  2. Analyze root cause
  3. Develop fix strategy
  4. Implement fix in staging
  5. Test fix thoroughly
  6. Deploy to staging environment
  7. Request tester re-verification
  8. Document fix in change log
  
  Example Timeline (12 hours):
    Hour 0: Issue identified
    Hour 2: Root cause analysis complete
    Hour 4: Fix developed and tested
    Hour 6: Fix deployed to staging
    Hour 8: Retesting by security team
    Hour 10: Tester verification
    Hour 12: Documented and closed

PHASE 3: HIGH PRIORITY FIXES (Within 1 week)
  For HIGH vulnerabilities:
  1. Schedule fix deployment
  2. Develop and test remediation
  3. Plan deployment to staging
  4. Execute fix
  5. Verify with automated scans
  6. Request tester re-verification (if applicable)
  7. Update tracking spreadsheet

PHASE 4: MEDIUM PRIORITY FIXES (2-4 weeks)
  For MEDIUM vulnerabilities:
  1. Include in normal development sprints
  2. Develop proper fixes (not quick patches)
  3. Test thoroughly in staging
  4. Deploy when ready
  5. Track in JIRA/project management system

PHASE 5: LOW/INFORMATIONAL (Backlog)
  For LOW and INFORMATIONAL findings:
  1. Include in future sprints
  2. Prioritize based on effort vs benefit
  3. Document in security backlog
  4. Track for annual review

PHASE 6: RE-VERIFICATION (Optional)
  If tester performs re-verification:
  1. Provide fix details to tester
  2. Tester verifies fix effectiveness
  3. Additional testing confirming fix
  4. Tester provides closure confirmation
  5. Mark finding as "Resolved" in report

PHASE 7: FINAL SIGN-OFF (Before production)
  Before production deployment:
  1. All CRITICAL -> Resolved
  2. All HIGH -> Resolved or Risk Accepted
  3. All MEDIUM -> Resolved or Risk Accepted (with approval)
  4. Compliance Officer review and approval
  5. Legal review if required
  6. Security lead final sign-off
```

### 3.3 Risk Acceptance Process

**If vulnerability cannot be fixed immediately (rare):**

```
RISK ACCEPTANCE PROCEDURE:

Criteria for Risk Acceptance:
  ✅ Business justification documented
  ✅ Compensating control in place
  ✅ Remediation timeline within 30 days
  ✅ NOT APPLICABLE to CRITICAL findings (unacceptable)
  ✅ Requires executive C-level approval

Risk Acceptance Form:

  ┌─────────────────────────────────────────────────────────┐
  │ VULNERABILITY RISK ACCEPTANCE                           │
  │                                                         │
  │ Finding: [Title]                                       │
  │ CVSS Score: [Score] - Severity: [Level]               │
  │ Tester Finding ID: [#]                                │
  │                                                        │
  │ Description:                                           │
  │ [Detailed vulnerability description]                   │
  │                                                        │
  │ Why Cannot Be Fixed Immediately:                       │
  │ [Business/technical reason - MAX 100 words]            │
  │                                                        │
  │ Compensating Controls Currently In Place:              │
  │ □ Access restrictions (limited users affected)         │
  │ □ Network segmentation (isolated environment)          │
  │ □ Monitoring/alerting (detects exploitation)          │
  │ □ Incident response procedures (recovery plan)         │
  │ □ Insurance coverage (financial protection)            │
  │ □ Other: _______________________________               │
  │                                                        │
  │ Remediation Plan & Timeline:                           │
  │ Action: [Fix to implement]                            │
  │ Target Date: [Within 30 days]                         │
  │                                                        │
  │ Residual Risk Level: [Acceptable/Monitor]             │
  │                                                        │
  │ Approvals:                                            │
  │ CISO/Security Lead: ______ Signature    Date: ___    │
  │ Compliance Officer: ______ Signature    Date: ___    │
  │ General Counsel: ______ Signature       Date: ___    │
  │ CFO (if significant risk): _____ Signature Date: ___ │
  │ CEO/Executive (if HIGH+): _____ Signature Date: ___  │
  │                                                        │
  │ Acceptance Status: [✅ APPROVED] [❌ DENIED]          │
  │                                                        │
  │ Notes:                                                │
  │ ___________________________________________________    │
  │                                                        │
  └─────────────────────────────────────────────────────────┘
```

---

## Part 4: Pre-Testing Preparation Checklist

### 4.1 Environment Preparation (4 weeks before)

```
STAGING ENVIRONMENT SETUP:

Network & Access:
  [ ] Staging environment isolated from production
  [ ] Tester IP addresses whitelisted on VPN
  [ ] Network ACLs prevent production access
  [ ] Staging monitoring/logging configured
  [ ] Kill switch procedures documented

Data Preparation:
  [ ] Synthetic PHI dataset created (anonymized)
  [ ] Sample genomic data without real patient info
  [ ] Database loaded with ~10K+ test records
  [ ] Backup of baseline environment created
  [ ] Data refresh mechanism automated nightly

Application Readiness:
  [ ] All code deployed to staging (matches planned production)
  [ ] Containers built and deployed
  [ ] SSL certificates installed (even if self-signed)
  [ ] APIs responding on defined endpoints
  [ ] Database connectivity verified
  [ ] Logs being collected (Prometheus, audit logs)

Monitoring Setup:
  [ ] Prometheus configured and collecting metrics
  [ ] Grafana dashboards created (uptime, errors, latency)
  [ ] Alert rules enabled for anomalies
  [ ] Security logging enabled (audit logs for test activities)
  [ ] Anomaly detection configured (excess queries, failed logins)

Incident Response:
  [ ] On-call team identified and briefed
  [ ] Escalation procedures documented
  [ ] Kill switch tested (can stop testing if needed)
  [ ] Contact procedures established (24/7)
  [ ] Recovery procedures tested

Documentation:
  [ ] System architecture diagram created
  [ ] API endpoint listing provided to tester
  [ ] Technology stack document prepared
  [ ] Known issues/assumptions documented
  [ ] Test credentials prepared (temporary, revokable)
```

### 4.2 Legal & Contractual Preparation (3 weeks before)

```
AGREEMENTS & LEGAL:

Penetration Testing Agreement:
  [ ] Scope clearly defined
  [ ] ROE (Rules of Engagement) document finalized
  [ ] Liability limitations agreed
  [ ] NDA signed by both parties
  [ ] Data destruction agreement executed
  [ ] Testing window dates/times locked in

Vendor Documentation:
  [ ] Certificate of Insurance received and verified
    - General Liability: $1M minimum
    - Professional Liability: $2M minimum
    - Certificate current: Yes / No
    - Expiration date: ___________
  [ ] Proof of HIPAA training provided
  [ ] References contacted and verified
  [ ] Vendor background check completed

Authorization Chain:
  [ ] Compliance Officer approval: _____ Date: ___
  [ ] CISO/Security Lead approval: _____ Date: ___
  [ ] General Counsel approval: _____ Date: ___
  [ ] Finance/Procurement approval: _____ Date: ___
  [ ] Invoice authorization verified: Yes / No

Insurance & Risk:
  [ ] Business interruption insurance checked
  [ ] Cybersecurity insurance policy reviewed
  [ ] Coverage limits confirmed adequate
  [ ] Claims procedures documented
```

### 4.3 Communication & Coordination (2 weeks before)

```
KICKOFF PREPARATION:

Internal Team Briefing:
  [ ] Security team briefed on scope
  [ ] Development team aware of testing window
  [ ] Operations team ready for on-call
  [ ] Database team understands data preparation
  [ ] Network team aware of tester IP access

External Communication:
  [ ] Kickoff meeting scheduled (1 hour)
  [ ] Tester receives documentation package:
    ☐ Environment access details
    ☐ API endpoint listing
    ☐ Architecture diagrams
    ☐ Known system limitations
    ☐ Escalation contact procedures
  [ ] Testing boundaries confirmed
  [ ] Status meeting frequency agreed (daily updates)
  [ ] Communication channels established:
    ☐ Primary: [Name, Phone, Email]
    ☐ Secondary: [Name, Phone, Email]
    ☐ Escalation: [Name, Phone, Email]

Final Walkthrough:
  [ ] Demo of staging environment to tester
  [ ] Database access verified
  [ ] API endpoints tested (GET requests)
  [ ] VPN connectivity confirmed
  [ ] Monitoring/logging verified operational
  [ ] Kill switch tested

Contingency Planning:
  [ ] Backup contact info for all on-call team
  [ ] Emergency procedures documented
  [ ] Rollback procedures tested
  [ ] Escalation matrix created
  [ ] Decision-maker availability confirmed
```

---

## Part 5: Post-Testing & Report Review

### 5.1 Report Receipt & Initial Review

```
UPON RECEIVING PENETRATION TEST REPORT:

Immediate Assessment (Day 1):
  1. Verify report completeness
     ☐ Executive summary present
     ☐ Detailed findings section
     ☐ Technical appendix
     ☐ All vulnerabilities have CVSS scores
     ☐ Proof-of-concept information included

  2. Validate findings accuracy
     ☐ Review sample findings in detail
     ☐ Reproduce 2-3 findings independently
     ☐ Confirm severity ratings are accurate
     ☐ Check for false positives

  3. Identify critical issues
     ☐ List all CRITICAL findings (should be few/none)
     ☐ Prioritize HIGH findings
     ☐ Note any findings affecting production

  4. Initial triage meeting
     ☐ Security team reviews report
     ☐ Development team reviews technical details
     ☐ Management briefed on severity
     ☐ Remediation strategy initiated
```

### 5.2 Report Follow-Up with Tester

```
CLARIFICATION & VALIDATION MEETING:

Tester Interview (Day 2-3):
  Schedule 1-2 hour meeting with test lead to:
  
  1. Clarify any unclear findings
     Q: "Can you walk through the exploitation steps for Finding #3?"
     Q: "What systems were accessible after initial compromise?"
     Q: "Did you identify the root cause of this vulnerability?"

  2. Validate severity ratings
     Q: "Why is this rated CRITICAL vs HIGH?"
     Q: "What is the realistic attack scenario?"
     Q: "How quickly could this be exploited?"

  3. Understand scope
     Q: "Were all defined systems tested?"
     Q: "Did you encounter any access limitations?"
     Q: "What areas were not covered?"

  4. Assess remediation recommendations
     Q: "What is your recommended fix for this?"
     Q: "Are there quick wins we should prioritize?"
     Q: "Can we remediate while in staging?"

  5. Discuss re-verification (optional)
     Q: "Can you re-test if we fix these by [date]?"
     Q: "What is your availability for follow-up?"
     Q: "What would re-testing cost?"

  Document Answers:
    - Record meeting notes
    - Request written clarifications for complex findings
    - Confirm final report is accurate
```

### 5.3 Creating Remediation Tracking

```
REMEDIATION TRACKING SPREADSHEET:

┌─────────────────────────────────────────────────────────────────┐
│ PENETRATION TEST REMEDIATION TRACKER                            │
│ Project: TheraGenome                                           │
│ Report Date: [DATE]                                            │
│ Tracking Status: [   ]% Complete                               │
└─────────────────────────────────────────────────────────────────┘

| ID | Finding | Severity | CVSS | Root Cause | Owner | Timeline | Status |
|----|---------|----------|------|-----------|-------|----------|--------|
| 1  | SQL Injection in patient_id parameter | CRITICAL | 9.2 | Input validation missing | Dev-Lead | Mar 8 | ✅ FIXED |
| 2  | Missing TLS on internal API | HIGH | 7.8 | Self-signed cert not loaded | Ops | Apr 5 | ⏳ IN PROGRESS |
| 3  | Weak password policy | MEDIUM | 5.2 | Policy not enforced in code | Dev | Apr 15 | ⏳ SCHEDULED |
| ... | ... | ... | ... | ... | ... | ... | ... |

Tracking Status:
  ✅ FIXED - Remedy applied, verified in staging
  ⏳ IN PROGRESS - Currently being fixed
  ⏳ SCHEDULED - Timeline assigned, work not started
  ⚠️ RISK ACCEPTED - Approved to proceed with known risk
  ❌ BLOCKED - Cannot remediate, escalation needed

Weekly Status Updates:
  Week 1 (Apr 2-6): CRITICAL items fixed, HIGH items started
  Week 2 (Apr 9-13): All HIGH items fixed or risk-accepted
  Week 3 (Apr 16-20): MEDIUM items underway, final verification
  Week 4 (Apr 23-27): Ready for production sign-off
```

---

## Part 6: Pre-Production Validation Gate

### 6.1 Sign-Off Checklist

```
BEFORE MOVING TO PRODUCTION, VERIFY:

☐ CRITICAL Findings: ALL fixed AND re-verified (0 outstanding)
☐ HIGH Findings: ALL fixed, risk-accepted, OR have mitigation
☐ MEDIUM Findings: ALL fixed OR risk-accepted OR deferred to backlog
☐ Report Accuracy: Confirmed no false positives
☐ Remediation Quality: Fixes properly implemented, not band-aids
☐ Re-verification: Tester confirms fixes are effective (if requested)
☐ Security Team Sign-Off: Security lead verified all fixes
☐ Development Lead Sign-Off: Dev lead confirmed code quality
☐ Compliance Officer Sign-Off: Compliance verified HIPAA alignment
☐ Legal Review: Legal counsel confirmed liability satisfied
☐ Testing Phase Complete: No ongoing testing activities

FINAL APPROVAL SIGNATURES:

CISO/Security Lead Approval:
  I confirm all penetration testing findings have been reviewed, 
  remediated appropriately, and the system is ready for production 
  deployment from a security perspective.
  
  Signature: _________________________ Date: _________
  

Compliance Officer Approval:
  I confirm this system meets HIPAA security requirements per 45 CFR 
  §164.308(a)(3) and penetration testing has been conducted to 
  satisfaction.
  
  Signature: _________________________ Date: _________


General Counsel Approval:
  I confirm all contractual and liability issues with the penetration 
  testing firm have been resolved and we are satisfied with their 
  work quality.
  
  Signature: _________________________ Date: _________


Development/Technical Lead Approval:
  I confirm all fixes have been properly implemented in the codebase 
  and are production-ready.
  
  Signature: _________________________ Date: _________

═══════════════════════════════════════════════════════════════════
FINAL STATUS: ✅ APPROVED FOR PRODUCTION
═══════════════════════════════════════════════════════════════════
```

---

## Part 7: Timeline & Next Steps

**Item 8 Implementation Timeline:**

```
WEEK 1-2 (Apr 2-13): VENDOR SELECTION & CONTRACTING
  ☐ Finalize RFP
  ☐ Send to 3-5 security firms
  ☐ Receive proposals
  ☐ Evaluate vendors
  ☐ Select preferred vendor
  ☐ Negotiate contract
  ☐ Sign agreement & insurance verification

WEEK 3-5 (Apr 14-May 2): ENVIRONMENT PREPARATION
  ☐ Staging environment setup
  ☐ Data preparation (synthetic PHI)
  ☐ Monitoring & logging configured
  ☐ Incident response team briefing
  ☐ Final walkthroughs
  ☐ Tester access provisioned

WEEK 6-8 (May 3-19): PENETRATION TESTING EXECUTION
  ☐ Kickoff meeting (Day 1)
  ☐ Reconnaissance phase (Days 1-3, 2-3 days)
  ☐ Scanning phase (Days 4-5, 1-2 days)
  ☐ Active testing phase (Days 6-10, 3-5 days)
  ☐ Post-exploitation (Days 11-13, 2-3 days)
  ☐ Report writing (Days 14-17, ongoing)
  ☐ Report delivery (Day 21)

WEEK 9-10 (May 20-June 2): FINDINGS ASSESSMENT & TRIAGE
  ☐ Report received and reviewed
  ☐ Initial triage completed
  ☐ Critical findings identified
  ☐ Follow-up meeting with tester
  ☐ Remediation tracking setup

WEEK 11-14 (June 3-30): REMEDIATION PHASE
  ☐ CRITICAL fixes deployed (immediate)
  ☐ HIGH fixes deployed (1 week)
  ☐ MEDIUM fixes deployed (2-4 weeks)
  ☐ Re-verification (if applicable)
  ☐ Final security team review
  ☐ Sign-offs collected

WEEK 15 (July 1-7): PRE-PRODUCTION VALIDATION
  ☐ All fixes verified in staging
  ☐ Final compliance review
  ☐ Sign-off gate passed
  ☐ Approved for production

TOTAL TIMELINE: 15 weeks (Vendor selection → Production-ready)
CONCURRENT WITH: Items 7 & 10 (BAA, Compliance Sign-off)
```

---

## Task 8 Summary

**Item 8 Status:** ⏳ IN PROGRESS - Vendor Selection Phase

**Critical Actions This Week (Apr 2-6):**
1. ✅ Finalize RFP document (provided above)
2. ⏳ Identify 3-5 security firms with HIPAA experience
3. ⏳ Send RFP with 2-week response deadline
4. ⏳ Begin vendor qualification process

**Success Criteria:**
- [ ] RFP issued to 3+ firms
- [ ] Proposals received by Apr 16
- [ ] Vendor selected by Apr 20
- [ ] Contract signed by May 1
- [ ] Testing begins May 3 (estimated)

**Compliance Impact:**
✅ Demonstrates HIPAA security evaluation requirement (45 CFR §164.308(a)(3))
✅ Identifies vulnerabilities before production
✅ Enables rapid remediation before launch
✅ Provides evidence of security due diligence

**Next:** Issue RFP to security firms, run parallel with Item 7 (BAA) execution
